TimesSquare Capital Management LLC Has $76.41 Million Stock Position in argenx SE (NASDAQ:ARGX)

TimesSquare Capital Management LLC lifted its position in shares of argenx SE (NASDAQ:ARGX) by 13.5% in the fourth quarter, Holdings Channel reports. The institutional investor owned 124,245 shares of the company’s stock after acquiring an additional 14,755 shares during the period. argenx makes up about 1.1% of TimesSquare Capital Management LLC’s portfolio, making the stock its 26th largest position. TimesSquare Capital Management LLC’s holdings in argenx were worth $76,411,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Global Retirement Partners LLC lifted its holdings in shares of argenx by 369.2% during the fourth quarter. Global Retirement Partners LLC now owns 61 shares of the company’s stock worth $38,000 after buying an additional 48 shares in the last quarter. Venturi Wealth Management LLC acquired a new position in argenx in the fourth quarter valued at about $66,000. Truist Financial Corp raised its stake in argenx by 6.8% in the fourth quarter. Truist Financial Corp now owns 4,283 shares of the company’s stock valued at $2,634,000 after purchasing an additional 272 shares in the last quarter. Sanctuary Advisors LLC raised its stake in argenx by 18.3% in the fourth quarter. Sanctuary Advisors LLC now owns 2,441 shares of the company’s stock valued at $1,625,000 after purchasing an additional 377 shares in the last quarter. Finally, Nkcfo LLC acquired a new position in argenx in the fourth quarter valued at about $68,000. Institutional investors and hedge funds own 60.32% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently commented on ARGX. JMP Securities boosted their price target on argenx from $606.00 to $696.00 and gave the company a “market outperform” rating in a research note on Tuesday, January 14th. Guggenheim boosted their price target on argenx from $585.00 to $665.00 and gave the company a “buy” rating in a research note on Friday, November 1st. Wells Fargo & Company boosted their price target on argenx from $639.00 to $723.00 and gave the company an “overweight” rating in a research note on Thursday, December 19th. HC Wainwright reaffirmed a “buy” rating and issued a $717.00 price target (up previously from $670.00) on shares of argenx in a research note on Tuesday, January 14th. Finally, Scotiabank raised argenx from a “sector perform” rating to a “sector outperform” rating and boosted their target price for the stock from $439.00 to $715.00 in a research note on Tuesday, November 5th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, argenx presently has an average rating of “Moderate Buy” and an average price target of $658.39.

argenx Trading Down 0.1 %

NASDAQ:ARGX opened at $639.00 on Wednesday. The stock has a market cap of $38.83 billion, a P/E ratio of -726.14 and a beta of 0.58. The stock’s 50-day moving average is $640.74 and its 200-day moving average is $584.63. argenx SE has a 1-year low of $349.86 and a 1-year high of $678.21.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.